Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab.
Target Oncol
; 11(4): 553-6, 2016 08.
Article
em En
| MEDLINE
| ID: mdl-26940583
ABSTRACT
Anti-programmed cell death-1 (PD-1) antibodies pembrolizumab and nivolumab are becoming increasingly important in the treatment of melanoma and non-small cell lung cancer. These agents are known to induce many immune-related adverse events, but rapid-onset nephritis and immune-related hyponatremia have not been described to date. We describe the case of an adult patient who developed severe hyponatremia and rapid-onset nephritis following the first infusion of nivolumab for metastatic melanoma.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hiponatremia
/
Anticorpos Monoclonais
/
Nefrite
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article